D A Breems
Overview
Explore the profile of D A Breems including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
228
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Aug;
34(10):2820.
PMID: 32733013
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
2.
Ossenkoppele G, Breems D, Stuessi G, van Norden Y, Bargetzi M, Biemond B, et al.
Leukemia
. 2020 Feb;
34(7):1751-1759.
PMID: 32020044
More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard chemotherapy might improve their outcome....
3.
Cornelissen J, Versluis J, Passweg J, van Putten W, Manz M, Maertens J, et al.
Leukemia
. 2014 Nov;
29(5):1041-50.
PMID: 25428261
The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher...
4.
Daenen S, van der Holt B, Dekker A, Willemze R, Rijneveld A, Biemond B, et al.
Leukemia
. 2012 Feb;
26(7):1726-9.
PMID: 22358264
No abstract available.
5.
Selleslag D, Dierickx D, Breems D, Huynh P, Van de Velde A, Meers S, et al.
Acta Clin Belg
. 2011 Aug;
66(3):200-4.
PMID: 21837928
Introduction: Currently available stem cell mobilizing regimens (G-CSF +/- chemotherapy) show high failure rates, especially in heavily pretreated patients. Plerixafor, a new stem cell mobilizing agent blocking the CXCR4-SDF-1 interaction,...
6.
Bromberg J, Breems D, Kraan J, Bikker G, van der Holt B, Sillevis Smitt P, et al.
Neurology
. 2007 May;
68(20):1674-9.
PMID: 17502548
Objective: To assess the diagnostic accuracy of flow cytometric immunophenotyping in comparison with classic cytomorphology for diagnosing CNS localizations of hematologic malignancies, and to evaluate the implications of CSF pleocytosis...
7.
van der Velden V, van Lom K, Hoogeveen P, Beverloo H, Breems D
Leukemia
. 2006 Jun;
20(9):1626-9.
PMID: 16791264
No abstract available.
8.
van Hennik P, Breems D, Kusadasi N, van den Berg H, van der Lelie H, Schipperus M, et al.
Br J Haematol
. 2000 Dec;
111(2):674-84.
PMID: 11122121
To analyse the involvement of a possible numerical or qualitative stem cell defect in the development of sustained graft failure after autologous transplantation, we have determined the graft content of...
9.
Breems D, Haye H, van der Meulen J
Neth J Med
. 2000 Mar;
56(2):38-44.
PMID: 10710938
Idiopathic retroperitoneal fibrosis is an uncommon inflammatory disease characterized by a periaortic fibrous mass throughout the retroperitoneum that often surrounds the ureters, leading to ureteral obstruction. An immune-mediated process has...
10.
Breems D, van Driel E, Hawley R, Siebel K, Ploemacher R
Leukemia
. 1998 Jun;
12(6):951-9.
PMID: 9639425
Mobilized peripheral blood stem cells (PBSC) are an attractive vehicle for cancer gene therapy. However these stem cells may have a reduced proliferative capacity due to previous cytotoxic chemotherapy treatment...